For pharma, big profits don't always translate to effective cybersecurity resources

Despite massive revenues across the sector, pharma companies face similar challenges and pushback from the board on cybersecurity resources — in spite of the high value of intellectual property.

Related Keywords

Eyad Elbayoumi ,Joe Mcmann ,Dave Cronin ,Pfizer ,Capgemini ,Health Insurance Portability ,Capgemini North ,European Medicines Agency ,